- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV2.7m8 variant Rep-Cap plasmid (inner ear&retina-validated serotype AAV-RC plasmid) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi's AAV2 variant (AAV2.7m8) Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV2 variant (AAV2.7m8) capsid protein.
You can produce AAV2 variant (AAV2.7m8) particle in 293T cell line in high titer using GeneMedi's AAV2 variant (AAV2.7m8) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV2.7m8 vector has been validated in inner ear and the retina tissue. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.
Go to AAV
vector system
>>
Map Download
Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | First Order Discount | First Order Discount Price |
|---|---|---|---|---|---|
| P-RC06 | AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance) Size：5ug | Academic | 1719 | 50% | 859.5 |
| P-RC06 | AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance) Size：5ug | Biotech & Pharma & Medical Device & Diagnostics | 50% | ||
| P-RC06 | AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance) Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
50% | ||
| P-RC06 | AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance) Size：≥10mg |
All | |||
| P-RC06-Kan | AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Kan resistance) Size：≥10mg |
All | |||
| P-PK06 | AAV2 variant (AAV2.7m8) Vector
System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug |
Academic | 3024 | 50% | 1512 |
| P-PK06 | AAV2 variant (AAV2.7m8) Vector
System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Biotech & Pharma & Medical Device & Diagnostics | 50% | ||
| P-PK06 | AAV2 variant (AAV2.7m8) Vector
System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
50% | ||
| P-PK06 | AAV2 variant (AAV2.7m8) Vector
System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK06-Kan | AAV2 variant (AAV2.7m8) Vector
System(Kan resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid(Kan resistance), ≥10mg 2. AAV Helper Plasmid(Kan resistance), ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| METTL3-mediated N6-methyladenosine mRNA modification enhances long-term memory consolidation | Cell Research | 2018/10/8 |
| Neuraminidase 1 is a driver of experimental cardiac hypertrophy | European Heart Journal | 2021/6/28 |
| LPA2 Contributes to Vascular Endothelium Homeostasis and Cardiac Remodeling After Myocardial Infarction | Circulation Research | 2022/8/19 |
| TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer | Science Translational Medicine | 2022/1/5 |
| Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN | Journal of Hematology&Oncology | 2021/3/19 |
| B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5-β-catenin pathway | Cell Death & Differentiation | 2022/6/16 |
| N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis | Nature Communications | 2022/3/18 |
| Targeting STING-mediated pro-inflammatory and pro-fibrotic effects of alveolar macrophages and fibroblasts blunts silicosis caused by silica particles | Journal of Hazardous Materials | 2023/6/22 |
| Hepatocyte CD36 modulates UBQLN1-mediated proteasomal degradation of autophagic SNARE proteins contributing to septic liver injury | Autophagy | 2023/4/4 |
| miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1 | Journal of Experimental & Clinical Cancer Research | 2023/5/2 |
Validation data
No data found
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
